...

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

【24h】

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

机译：达那妥单抗联合来那度胺联合地塞米松或硼替佐米联合地塞米松治疗的复发/难治性多发性骨髓瘤（RRMM）患者的最低残留疾病（MRD）评估

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Avet-Loiseau Herve; Casneuf Tineke; Chiu Christopher; Laubach Jacob P.; Lee Je-Jung; Moreau Philippe; Plesner Torben; Nahi Hareth; Khokhar Nushmia Z.; Qi Ming; Schecter Jordan; Carlton Victoria; Qin Xiang; Liu Kevin; Wu Kaida; Zhuang Sen H.; Ahmadi Tahamtan; Sasser A. Kate; San-Miguel Jesus;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor [J] . Avet-Loiseau Herve, San-Miguel Jesus F., Casneuf Tineke, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用达拉姆珠三任骨（RRMM）与Lenalalomide Plus地塞米松（D-Rd）或Bortezomib加上地塞米松（D-VD）组合治疗的复发/难治性多发性疾病（RRMM）患者（RRMM）患者（RRMM）患者（RRMM）患者（RRMM）患者（RRMM）患者（PTS）的评估持续最小的和脚轮
2. Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM) [J] . Bahlis Nizar, Dimopoulos Meletios A., White Darrell J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：三年后，达拉努马替少米德和地塞米松（D-Rd）对甲二烯酰胺和地塞米松（D-Rd）的三年进行跟踪，单独在复发或难治性多骨髓瘤（RRMM）中
3. Overall Survival (OS) Benefit of Oral Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) Vs Lenalidomide and Dexamethasone (Rd) in Asian Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Pooled-Analysis from the Tourmaline-MM1 and the China Continuation Studies [J] . Fu Weijun, Lu Jin, Jin Jie, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：口腔Ixazomib的整体存活（OS）益处与Lenalalomide和Dexamethasone（IRD）与亚洲患者（PTS）组合的亚洲患者（PTS）的益处（PTS）组合，具有复发和/或难治性多骨髓瘤（RRMM）：汇总 - 从陀螺俱乐部分析 - MM1和中国延续研究
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023 [O] . Maria-Victoria Mateos, David Siegel, Jatin J Shah, 2015

机译：派姆单抗（MK-3475）联合来那度胺和小剂量地塞米松治疗复发/难治性多发性骨髓瘤（RRMM）：KEYNOTE-023
7. Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR [O] . K. Weisel, A. Palumbo, A. Chanan-Khan, 2016

机译：患者（PTS）中达拉姆宫，硼替佐米和地塞米松（DVD）和硼替米布（DVD）和地塞米松（VD）的第3阶段随机研究，复发或难治多骨髓瘤（RRMM）：蓖麻

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号